ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries.  The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.  

“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek.  “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”          

Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market.  With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.” 

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?